270 related articles for article (PubMed ID: 27799565)
1. Fusion transcriptome profiling provides insights into alveolar rhabdomyosarcoma.
Xie Z; Babiceanu M; Kumar S; Jia Y; Qin F; Barr FG; Li H
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13126-13131. PubMed ID: 27799565
[TBL] [Abstract][Full Text] [Related]
2. A chimeric RNA characteristic of rhabdomyosarcoma in normal myogenesis process.
Yuan H; Qin F; Movassagh M; Park H; Golden W; Xie Z; Zhang P; Sklar J; Li H
Cancer Discov; 2013 Dec; 3(12):1394-403. PubMed ID: 24089019
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of PAX3/7-FOXO1 fusion status in alveolar rhabdomyosarcoma: Systematic review and meta-analysis.
Kubo T; Shimose S; Fujimori J; Furuta T; Ochi M
Crit Rev Oncol Hematol; 2015 Oct; 96(1):46-53. PubMed ID: 26008753
[TBL] [Abstract][Full Text] [Related]
4. Acquisition of an oncogenic fusion protein serves as an initial driving mutation by inducing aneuploidy and overriding proliferative defects.
Loupe JM; Miller PJ; Bonner BP; Maggi EC; Vijayaraghavan J; Zabaleta J; Taylor CM; Tsien F; Crabtree JS; Hollenbach AD
Oncotarget; 2016 Sep; 7(39):62814-62835. PubMed ID: 27588498
[TBL] [Abstract][Full Text] [Related]
5. Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma.
Kephart JJ; Tiller RG; Crose LE; Slemmons KK; Chen PH; Hinson AR; Bentley RC; Chi JT; Linardic CM
Clin Cancer Res; 2015 Nov; 21(21):4868-80. PubMed ID: 26071485
[TBL] [Abstract][Full Text] [Related]
6. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Ahn EH
Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752
[TBL] [Abstract][Full Text] [Related]
7. [Alveolar rhabdomyosarcoma: Two fusion-negative cases lacking PAX3-FOXO1 and PAX7-FOXO1].
Mestre-Alagarda C; Gómez-Mateo MC; Berenguer-Romero MD; Syonghyun NC; Nieto G; Navarro-Fos S
Rev Esp Patol; 2022; 55(1):57-62. PubMed ID: 34980443
[TBL] [Abstract][Full Text] [Related]
8. Regulatory landscape fusion in rhabdomyosarcoma through interactions between the PAX3 promoter and FOXO1 regulatory elements.
Vicente-García C; Villarejo-Balcells B; Irastorza-Azcárate I; Naranjo S; Acemel RD; Tena JJ; Rigby PWJ; Devos DP; Gómez-Skarmeta JL; Carvajal JJ
Genome Biol; 2017 Jun; 18(1):106. PubMed ID: 28615069
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine Induces Apoptosis and Down-regulation of
Ahn EH; Lee MB; Seo DJ; Lee J; Kim Y; Gupta K
Anticancer Res; 2018 Jan; 38(1):71-76. PubMed ID: 29277758
[TBL] [Abstract][Full Text] [Related]
10. PAX3-FOXO1 escapes miR-495 regulation during muscle differentiation.
Xie Z; Tang Y; Su X; Cao J; Zhang Y; Li H
RNA Biol; 2019 Jan; 16(1):144-153. PubMed ID: 30593263
[TBL] [Abstract][Full Text] [Related]
11.
Kendall GC; Watson S; Xu L; LaVigne CA; Murchison W; Rakheja D; Skapek SX; Tirode F; Delattre O; Amatruda JF
Elife; 2018 Jun; 7():. PubMed ID: 29869612
[TBL] [Abstract][Full Text] [Related]
12. Loss of MST/Hippo Signaling in a Genetically Engineered Mouse Model of Fusion-Positive Rhabdomyosarcoma Accelerates Tumorigenesis.
Oristian KM; Crose LES; Kuprasertkul N; Bentley RC; Lin YT; Williams N; Kirsch DG; Linardic CM
Cancer Res; 2018 Oct; 78(19):5513-5520. PubMed ID: 30093562
[TBL] [Abstract][Full Text] [Related]
13. PAX3-FOXO1: Zooming in on an "undruggable" target.
Wachtel M; Schäfer BW
Semin Cancer Biol; 2018 Jun; 50():115-123. PubMed ID: 29146205
[TBL] [Abstract][Full Text] [Related]
14. PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization.
Dumont SN; Lazar AJ; Bridge JA; Benjamin RS; Trent JC
J Cancer Res Clin Oncol; 2012 Feb; 138(2):213-20. PubMed ID: 22089931
[TBL] [Abstract][Full Text] [Related]
15. Reduced B7-H3 expression by PAX3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcoma.
Kanayama T; Miyachi M; Sugimoto Y; Yagyu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
Sci Rep; 2021 Sep; 11(1):18802. PubMed ID: 34552155
[TBL] [Abstract][Full Text] [Related]
16. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.
Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG
J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962
[TBL] [Abstract][Full Text] [Related]
17. Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma.
Singh S; Abu-Zaid A; Jin H; Fang J; Wu Q; Wang T; Feng H; Quarni W; Shao Y; Maxham L; Abdolvahabi A; Yun MK; Vaithiyalingam S; Tan H; Bowling J; Honnell V; Young B; Guo Y; Bajpai R; Pruett-Miller SM; Grosveld GC; Hatley M; Xu B; Fan Y; Wu G; Chen EY; Chen T; Lewis PW; Rankovic Z; Li Y; Murphy AJ; Easton J; Peng J; Chen X; Wang R; White SW; Davidoff AM; Yang J
Sci Transl Med; 2022 Jul; 14(653):eabq2096. PubMed ID: 35857643
[TBL] [Abstract][Full Text] [Related]
18. FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.
Milewski D; Shukla S; Gryder BE; Pradhan A; Donovan J; Sudha P; Vallabh S; Pyros A; Xu Y; Barski A; Szabo S; Turpin B; Pressey JG; Millay DP; Khan J; Kalinichenko VV; Kalin TV
Oncogene; 2021 Mar; 40(12):2182-2199. PubMed ID: 33627785
[TBL] [Abstract][Full Text] [Related]
19. Transgenic mice expressing PAX3-FKHR have multiple defects in muscle development, including ectopic skeletal myogenesis in the developing neural tube.
Finckenstein FG; Davicioni E; Osborn KG; Cavenee WK; Arden KC; Anderson MJ
Transgenic Res; 2006 Oct; 15(5):595-614. PubMed ID: 16952014
[TBL] [Abstract][Full Text] [Related]
20. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
